Short Summary
Novartis sought an interim injunction restraining Mehar Pharma from manufacturing, selling, or exporting its anti-cancer drug 'VEENAT', which was alleged to infringe Novartis's Exclusive Marketing Rights (EMR) for 'B-crystalline form of imatinib Mesyiate salt'. The court ultimately denied the temporary injunction, citing concerns about disrupting the supply of this life-saving drug in India.
Detailed Summary
In the high-stakes world of pharmaceuticals, patent battles can mean life or death—literally. When a multinational drug giant claims exclusive rights to a cancer medication, and a domestic manufacturer steps in to make it affordable, who should the courts side with? This landmark dispute between Novartis AG and Mehar Pharma forced the judiciary to confront a deeply uncomfortable question: can the law protect corporate exclusivity when doing so might cut off a life-saving drug from the patients who need it most?
Novartis AG, a global pharmaceutical powerhouse, held Exclusive Marketing Rights (EMR) for the 'B-crystalline form of imatinib Mesylate salt'—the active compound used in a breakthrough anti-cancer drug. These exclusive rights gave Novartis the legal authority to be the sole marketer of this formulation in India. Meanwhile, Mehar Pharma, an Indian pharmaceutical company, began manufacturing, selling, and exporting its own version of the anti-cancer drug under the brand name 'VEENAT'. Novartis viewed this as a direct infringement of its exclusive marketing rights and moved swiftly to seek legal recourse. The stage was set for a confrontation that would pit international intellectual property claims against domestic public health imperatives.
Novartis argued that Mehar Pharma's production and distribution of 'VEENAT' violated its Exclusive Marketing Rights for the B-crystalline form of imatinib Mesylate salt. As the holder of these exclusive rights, Novartis contended that no other entity should be permitted to market this specific formulation without authorization. On the other side, Mehar Pharma defended its right to manufacture and supply the drug, emphasizing its critical role in making the anti-cancer medication accessible to patients in India. The core legal friction was not merely about intellectual property—it was about whether the court should enforce exclusive marketing rights at the potential cost of disrupting the supply chain of a drug that cancer patients relied upon for their treatment and survival.
On 23 December 2004, the court delivered its decision, and it was not what Novartis had hoped for. The court denied Novartis's request for an interim injunction, effectively allowing Mehar Pharma to continue manufacturing, selling, and exporting 'VEENAT'. The court's reasoning centered on a critical balancing act: the granting of a temporary injunction must carefully weigh the interests of both parties, particularly when the drug in question is essential or life-saving. The court recognized that one party was an importer while the other was a domestic manufacturer, and disrupting the supply of this anti-cancer medication could have devastating consequences for patients who depended on it. By denying the injunction, the court prioritized the continuity of access to a life-saving drug over the enforcement of exclusive marketing rights—at least at the interim stage.
For founders, startup leaders, and IP professionals, this case delivers a powerful lesson: exclusive rights and patents, no matter how strongly held, are not absolute shields—especially in sectors where public health is at stake. If your business operates in pharmaceuticals or any essential goods sector, understand that courts may weigh the broader social impact of injunctions heavily. Before pursuing aggressive interim relief, consider whether your product is life-saving or essential, and whether the opposing party serves a critical role in the supply chain. Strategic litigation is not just about legal entitlement; it is about anticipating how courts will balance commercial rights against public welfare. Build your IP strategy with this reality in mind.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Bombay High Court. Understanding the court's reasoning in Novartis Ag And Anr. vs Mehar Pharma And Anr. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
The North Face Apparel CorpvsController of Patents and Designs
The North Face Apparel Corp challenged the Controller of Patents' refusal of its patent application (No. 202147026139) titled 'Systems and Methods for End-to-End Article Management' before the Madras High Court under Section 117A of the Patents Act, 1970. The Controller had rejected the application citing lack of inventive step over prior art documents D21-D24. The Court held that the Controller erred by dissecting the claims into isolated elements rather than assessing the invention as a whole, and overlooked the use of spectrophotometer and invisible markers for tracking the manufacturing process, which were not disclosed in the cited prior art. The appeal was allowed and the Controller was directed to grant the patent.
Aventose Energy Private LimitedvsThe Assistant Controller of Patents & Designs, Patent Office Chennai
Aventose Energy Private Limited appealed under Section 117A of the Patents Act, 1970 against the refusal of its patent application (No. 202141019671) for a 'System and Method for Operating Automobiles with an Electric Drivetrain' featuring safe mode activation upon fault detection. The Madras High Court found that the Assistant Controller had contradicted the First Examination Report (which accepted novelty) by subsequently holding the invention lacked novelty without giving the applicant an opportunity to be heard. The court further held that the Controller improperly conflated novelty with inventive step under Section 2(1)(ja) and failed to properly analyze the claims against prior art documents D1–D4.
Apex Laboratories Pvt LtdvsElder Lifescience and Ambico Ayurvedic Health Care
Apex Laboratories Pvt Ltd, the prior adopter and registered proprietor of the trademark ZINCOVIT (TM No. 487453 in Class 5) since 1988, sought interim injunction against Elder Lifescience and Ambico Ayurvedic Health Care for using the deceptively similar mark NEO ZINCOVIT. The applicant also claimed copyright infringement of its registered artistic works (A-108878/2014) covering colour scheme, get-up, and layout. The Madras High Court was satisfied that the respondents were attempting to piggyback on the applicant's goodwill and granted interim injunctions on all three applications covering trademark infringement, copyright infringement, and passing off.
Radico Khaitan LimitedvsPicadilly Agro Industries Limited
This Special Leave Petition arose from a judgment dated 29-05-2026 in CS No. 8/2025 passed by the District Judge, Karnal, Haryana, concerning a trademark dispute over the marks 'Cashmere' and 'Kashmyr' used in relation to beer and vodka. The Supreme Court noted that a First Appeal (FAO-COM-11-2026) was already pending before the Division Bench of the Punjab and Haryana High Court, listed for 28.10.2026. The Court disposed of the SLP without adjudicating it on merits, requesting the High Court to pass an appropriate order regarding the ad interim injunction on the scheduled date.
Maharaja Agrasen Technical Educational Society (Regd.)vsMaharaja Agrasen Himalayan Garhwal University
The plaintiff, Maharaja Agrasen Technical Educational Society, filed a suit for permanent injunction against the defendant, Maharaja Agrasen Himalayan Garhwal University, alleging infringement and passing off regarding the use of the words 'Maharaja Agrasen' in the defendant's name. The Delhi High Court had previously granted a restraint order on 10.07.2026. During the pendency of the suit, the parties arrived at a settlement dated 14.09.2026, under which the defendant agreed to change its name through a statutory amendment while being permitted limited transitional use of its existing name. The court recorded the settlement, modified the interim order accordingly, and listed the matter for compliance reporting on 13.07.2027.
Varahi Diamonds And Finance LimitedvsSahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr.
This is a commercial suit filed by Varahi Diamonds And Finance Limited against Sahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr. before the Delhi High Court. The order is primarily procedural, dealing with the registration of the plaint, issuance of summons, directions for filing pleadings, and an interim injunction application. The matter was referred to mediation, with parties directed to appear before the Delhi High Court Mediation and Conciliation Centre.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.